Quality of Life Program: National Cultural Awards culminates support to Saudi culture, intellectuals    KSrelief Continues Distributing Ramadan Food Baskets in Lebanon    King, Crown Prince condoles Turkmen president on death of his father    Two Holy Mosques Affairs General Presidency: Increasing capacity of Mataf Courtyard, allocating 4 paths for elderly    India Reports New High of 1,761 Daily COVID-19 Deaths    Russia reports 8,164 new COVID-19 cases, 379 deaths    Custodian of the Two Holy Mosques Directs Disbursement of SR 1.9 Billion of Ramadan Aid for Social Insurance Beneficiaries    China administered total of 195.02 mln COVID-19 vaccines as of April 19    Prince Khalid meets with UK PM's envoy to Gulf region    10 million people in UK receive second dose of COVID-19 vaccine    Video clip showing expats being assaulted is old: Riyadh Police    US immigration agencies ordered to end use of terms 'alien' and 'assimilation'    US warns against travel to 80% of all countries due to COVID-19 State Department 'strongly recommends' US citizens reconsider any travel aborad    Chairman of Libyan Presidential Council Meets with Algerian Foreign Minister    In Jeel Tamooh's third edition, BCG experts, 100 world-class Saudi students come together    UAE government adopts 'blockchain' technology in authentication services    KSrelief signs two joint agreements to serve needy people in Yemen    Jadwa Investment partners with MHRSD to develop non-profit sector    Oilfields Supply Center's $570m investment in SPARK    SRC Obtains Good Ratings From Moody's, Fitch    National Center for Privatization Hosts Chinese Investors Forum    Saudi Stock Exchange Main Index Ends Trading Higher at 10,097 Points    Diriyah Gate participates in Kingdom's celebration of the World Heritage Day    Saudi Al-Hilal Defeats UAE Shabab Al-Ahli witn AFC Champions League    Saudi Al-Ahli, Qatari Al-Duhail Drew 1-1    Messi fires Barca to dominant Cup final win    Bayern moves closer to title but Flick says he's leaving    IRTI Report Showcases Sustainable Development Goals for IsDB Member States    Bayern move closer to title but Flick says he's leaving    The importance of legal specialization    Indian actor and environmentalist Vivek dies at age of 59    Alert over shortage of new drugs for 'world's most dangerous bacteria'    Helen McCrory, 'Harry Potter' and 'Peaky Blinders' star, dead at 52    New global compact aims to drive down diabetes deaths, boost insulin access    Welcome to beautiful Ramadan customs    Foundation stone laid for Jeddah Formula One circuit    Laying the Foundation Stone for Jeddah Formula One Circuit    King Salman Center for Disability Research Launches 2nd Edition of its Story Collection (Awareness)    Riyadh Light Witnesses Conclusion of External Artworks    Riyadh Light Turned the Capital into Lights' Aura    Colored Triangles Decorate Conference Building, at King Abdullah Financial Center    Vaccination does not invalidate fasting, says UAE Fatwa Council    It is high time to correct wrong concepts about women's status    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Court facilitates young woman's marriage after stripping father's guardianship    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    Pilgrims Perform Dhuhr and Asr Prayers in Arafat Holy Site    Senior Scholars Council Issues Decision No. 246 Regarding Attendance of Friday Prayer and Prayers at Mosques in a Case of Spread of Epidemic or Fear of its Spread    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





RDIF, Pharco agree to supply 25 million doses of Sputnik V vaccine to Egypt
Published in The Saudi Gazette on 30 - 09 - 2020

The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, and Pharco, one of the leading pharmaceutical groups in Egypt (acting through its key operational subsidiary – Biogeneric Pharma) have agreed to secure the supply of 25 million doses of the Sputnik V vaccine to Egypt.
The vaccine, which is based on a well-studied human adenoviral vectors platform with proven safety and efficacy, will support the efforts of the Ministry of Health of Egypt to secure a vaccine against COVID-19.
The agreement will enable 25% of Egypt's population to have access to the Sputnik V vaccine. In the future, it is planned to distribute it to neighboring countries.
Egypt will secure a diversified vaccine portfolio, which includes a vaccine based on the human adenoviral vectors platform. This platform has proven safe over decades including through 75 international scientific publications and in more than 250 clinical trials.
Clinical trials of the Russian vaccine have shown no serious adverse events, with Sputnik V generating a stable humoral and cellular immune response in 100% of participants. In contrast, vaccines based on novel platforms have yet to prove their safety and currently have no data on carcinogenicity or effects on fertility.
On Aug. 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world's first registered vaccine against COVID-19 based on the human adenoviral vectors platform.
Detailed information on the Sputnik V vaccine, the technological platform of human adenoviral vectors, and other details are available at sputnikvaccine.com
On Sept. 4, a research paper on the results of Phase I and Phase II clinical trials of the Sputnik V vaccine was published in The Lancet, one of the leading international medical journals.
Post-registration clinical trials of the Sputnik V vaccine involving 40,000 volunteers are currently ongoing. More than 60,000 volunteers have applied to take part in post-registration trials. The first results of these trials are expected to be published in October-November 2020.
More than 50 countries in the Middle East, Asia, Latin America, Europe and CIS have applied for Sputnik V. RDIF has already announced supply agreements with Mexico for 32 million doses, with Brazil for up to 50 million doses, India — 100 million doses, Uzbekistan — for up to 35 million doses and Nepal for 25 million doses.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said: "The agreement between RDIF and Pharco will help Egypt obtain an efficient and safe vaccine, Sputnik V, for almost 25% of its population. The adenoviral vectors platform has a longer safety track record compared to novel technologies such as monkey adenoviral vectors or mRNA used by other vaccine manufacturers.
"So the people of Egypt will get a proven vaccine created on a platform with no negative long-term effects, including carcinogenicity or risks for fertility in the future. We expect more countries to include Sputnik V in their vaccine portfolios in the coming weeks."
Dr. Sherine Abbas Helmy, founder and president of Pharco, said: "We greatly appreciate this agreement to secure supplies of the Russian Sputnik V vaccine with proven safety to Egypt. Besides vaccine supply, we are considering numerous further cooperation opportunities jointly with RDIF, including the localization of production in Egypt at the facilities of Biogeneric Pharma within the next few months for the benefit of both countries."
Feliks Ershov, virologist, and academician of the Russian Academy of Sciences, noted: "This pandemic will not be completely eradicated without a vaccine. The vaccine created by the Gamaleya Center is not one-piece, like the vaccines of the past, (containing a live or killed virus). It is made using modern biotechnology and a proven platform, in contrast to products by a number of companies based on mRNA or the monkey adenovirus, which have not been tested before.
"The safety of the Sputnik V vaccine is ensured by using a simple flu virus that is harmless to humans and does not contain the coronavirus itself — only a part of its genetic code, which excludes the possibility of infection. But the antibodies response necessary to protect the body is ensured, which was confirmed by the results of trials.
"The use of two consecutive shots with different mechanisms of delivery of the virus code into the body guarantees immunization and represents a unique advantage of the Russian vaccine." — PRNewswire


Clic here to read the story from its source.